EBITDA Margin % is calculated as EBITDA divided by its Revenue. Enorama Pharma AB's EBITDA for the
three
months ended in Mar. 2026 was kr-9.27 Mil. Enorama Pharma AB's Revenue for the
three
months ended in Mar. 2026 was kr-0.11 Mil. Therefore, Enorama Pharma AB's EBITDA margin for the quarter that ended in Mar. 2026 was 8,507.34%.
Enorama Pharma AB (OSTO:ERMA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Enorama Pharma AB EBITDA Margin % Related Terms
Enorama Pharma AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Enorama Pharma AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ERMA vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Enorama Pharma AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enorama Pharma AB EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enorama Pharma AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Enorama Pharma AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enorama Pharma AB (OSTO:ERMA) has a EBITDA Margin % of 8,507.34% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Enorama Pharma AB and its competitors. According to the industry distribution chart, Enorama Pharma AB ranks #937 out of 955 companies in the Drug Manufacturers industry, placing it in the top 98.1%.
Is Enorama Pharma AB's EBITDA Margin % too high?
Enorama Pharma AB's current EBITDA Margin % is 8,507.34%. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Enorama Pharma AB's value of 8,507.34% is 68287% above this industry median. Based on the distribution chart, Enorama Pharma AB ranks #937 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Enorama Pharma AB has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Enorama Pharma AB's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Enorama Pharma AB ranks #937 out of 955 companies for EBITDA Margin %. This places Enorama Pharma AB in the lower half of its industry. The industry median EBITDA Margin % is 12.44. Enorama Pharma AB's value of 8,507.34% is 68287% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enorama Pharma AB's current EBITDA Margin % of 8,507.34% is 68287% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Enorama Pharma AB and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enorama Pharma AB's current EBITDA Margin % is 8,507.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enorama Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Enorama Pharma AB (OSTO:ERMA) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.42, compared to a current price of kr0.26 — trading 39.3% below its estimated fair value. The current EBITDA Margin % is 8,507.34% and 68287% above the Drug Manufacturers industry median of 12.44. Enorama Pharma AB's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Enorama Pharma AB (OSTO:ERMA), the current EBITDA Margin % is 8,507.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enorama Pharma AB (OSTO:ERMA) Overvalued in 2026?
Based on GuruFocus' analysis, Enorama Pharma AB stock appears to be undervalued.
The current stock price of kr0.26 is trading 39.3% below its estimated GF Value™ of kr0.42.
GuruFocus considers Enorama Pharma AB to be Possible Value Trap.
Key valuation signals for OSTO:ERMA:
EBITDA Margin %: 8,507.34%
GF Value™: kr0.42 vs. price of kr0.26 (39.3% below fair value)
Industry Position: 68287% above the Drug Manufacturers median (#937 of 955)
No single metric tells the full story. See the OSTO:ERMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
28GF Score
Get the complete analysis for OSTO:ERMA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ERMA has been successfully added to your 
